Greg Verdine

Greg Verdine

Company: Fog Pharma

Job title: President, CEO and CSO


Join me at Wnt


Turning the Undruggable Druggable into the Next Blockbuster: β-Catenin 9:10 am

• Highlighting the importance of β-catenin as THE target in the Wnt pathway relevant to cancer • Providing approaches toward drugging β-catenin and other intractable targets, especially transcription factors • Sharing progress to date on drugging β-cateninRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.